Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Xenetic Biosciences, Inc.Financial_Report.xls
10-K - MAINBODY - Xenetic Biosciences, Inc.mainbody.htm
XML - IDEA: XBRL DOCUMENT - Xenetic Biosciences, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Xenetic Biosciences, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Xenetic Biosciences, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Xenetic Biosciences, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Xenetic Biosciences, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Xenetic Biosciences, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Xenetic Biosciences, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Xenetic Biosciences, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Xenetic Biosciences, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Xenetic Biosciences, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Xenetic Biosciences, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Xenetic Biosciences, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Xenetic Biosciences, Inc.R13.htm
EX-32.1 - EXHIBIT 32.1 - Xenetic Biosciences, Inc.ex32_1.htm
EX-31.2 - EXHIBIT 31.2 - Xenetic Biosciences, Inc.ex31_2.htm
EX-31.1 - EXHIBIT 31.1 - Xenetic Biosciences, Inc.ex31_1.htm
EX-10.2 - EXHIBIT 10.2 - Xenetic Biosciences, Inc.ex10_2.htm
v2.4.0.6
Balance Sheets (USD $)
Aug. 31, 2012
Aug. 31, 2011
Current Assets:    
Cash $ 32,005 $ 10,000
Accounts receivable 99,108   
Total current assets 131,113 10,000
Fixed Assets, net of accumulated depreciation of $19,481 and $0, respectively 193,019 212,500
Total assets 324,132 222,500
Current Liabilities:    
Accounts payable and accrued expenses 190,667 7,374
Accrued interest 13,560 548
Total current liabilities 204,227 7,922
Long-term debt 212,813 212,813
Total liabilities 417,040 220,735
Stockholders (Deficit) Equity    
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at August 31, 2012 and 2011, respectively      
Common stock, $0.001 par value; 90,000,000 shares authorized, 13,500,000 and 10,000,000 shares issued and outstanding at August 31, 2012 and 2011, respectively 13,500 10,000
Additional paid-in capital 31,500   
Deficit accumulated during development stage (137,908) (8,235)
Total stockholders (deficit) equity (92,908) 1,765
Total liabilities and stockholders (deficit) equity $ 324,132 $ 222,500